Results 91 to 100 of about 7,402 (232)
Breast cancer immunotherapy: Realities and advances
Cancer Innovation, Volume 3, Issue 5, October 2024.In this article, we aim to summarize the most recent data available in breast cancer immunotherapy, including the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments. Abstract Breast cancer (BC) is the most common malignant tumor and the main cause of death in women worldwide ...
Aixa Medina +4 more
wiley +1 more source
Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy
Journal of Biomedical Science, 2019 Oncolytic virotherapy has currently emerged as a promising approach upon which scientists have been able to induce tumor-specific cell death in a broad spectrum of malignancies.
Mohsen Keshavarz +3 more
doaj +1 more source
Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges
MedComm, Volume 5, Issue 10, October 2024.The rapid advancements in nanoengineering have ushered in a plethora of novel nanomaterials and nanotechnologies, invigorating the therapeutic potential of oncolytic viruses (OVs) especially including genetically engineered ones against tumors. Therein, beyond more robust and persistent antitumor response, genetically and chemically engineered OVs are ...
Yan Zhang +8 more
wiley +1 more source
Dampening effect of logistic source in a two-dimensional haptotaxis system with nonlinear zero-order interaction [PDF]
arXiv, 2020 This paper deals with the oncolytic virotherapy model \begin{equation}\begin{split} \begin{cases} &u_t = \Delta u - \nabla \cdot (u\nabla v)-uz +\mu u(1-u),& \\[2ex] &v_t = - (u+w)v,& \\[2ex] &w_t = D_w \Delta w - w + uz,& \\[2ex] &z_t = D_z \Delta z - z - uz + \beta w,& \end{cases} \end{split}\end{equation} in a bounded domain $\Omega$ $\subset$ $\Bbb{
arxiv
Current perspectives of virotherapy as a cancer treatment strategy
Инфекция и иммунитетAnalysis of scientific literature presented in the main databases (PubMed, CyberLeninka, Google Scholar, Scopus) evidence that after cardiovascular diseases malignant tumors hold the second place among the most common causes of mortality in both ...
Lyubov D. Vlasova
doaj +1 more source
Molecular Therapy: Oncolytics, 2017 Oncolytic virotherapy is a treatment approach with increasing clinical relevance, as indicated by the marked survival benefit seen in animal models and its current exploration in human patients with cancer.
Julius W. Kim +9 more
doaj +1 more source
Questing for an optimal, universal viral agent for oncolytic virotherapy [PDF]
arXiv, 2011 One of the most promising strategies to treat cancer is attacking it with viruses designed to exploit specific altered pathways. Here, the effects of oncolytic virotherapy on tumors having compact, papillary and disconnected morphologies are investigated through computer simulations of a multiscale model coupling macroscopic reaction diffusion ...
arxiv
Oncolytic virotherapy: the questions and the promise
Oncolytic Virotherapy, 2013 Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms.
openaire +4 more sources
Oncolytic Replication of E1b-Deleted Adenoviruses
Viruses, 2015 Various viruses have been studied and developed for oncolytic virotherapies. In virotherapy, a relatively small amount of viruses used in an intratumoral injection preferentially replicate in and lyse cancer cells, leading to the release of amplified ...
Pei-Hsin Cheng +3 more
doaj +1 more source
Redemption for the Field of Oncolytic Virotherapy
Molecular Therapy, 2011 The field of targeted and transgene-armed oncolytic viruses has been through a cycle of boom (mid-1990s) and bust (the early 2000s). In January 2011, however, Amgen—the biggest independent biotechnology company in the world—jumped headfirst into the field by acquiring Biovex for $425 million and promising potential success-based milestone payments of ...
openaire +3 more sources